Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TriSalus Life Sciences (TLSI) Debt to Equity (2022 - 2026)

TriSalus Life Sciences has reported Debt to Equity over the past 5 years, most recently at $2.58 for Q1 2026.

  • For Q1 2026, Debt to Equity rose 380.05% year-over-year to $2.58; the TTM value through Mar 2026 reached $2.58, up 380.05%, while the annual FY2025 figure was -$0.98, 14.43% down from the prior year.
  • Debt to Equity for Q1 2026 was $2.58 at TriSalus Life Sciences, up from -$0.98 in the prior quarter.
  • Over five years, Debt to Equity peaked at $2.58 in Q1 2026 and troughed at -$1.66 in Q2 2025.
  • A 5-year average of -$0.46 and a median of -$0.85 in 2024 define the central range for Debt to Equity.
  • Biggest five-year swings in Debt to Equity: crashed 1564.01% in 2024 and later skyrocketed 380.05% in 2026.
  • Year by year, Debt to Equity stood at -$0.01 in 2022, then crashed by 265.79% to -$0.05 in 2023, then crashed by 1584.32% to -$0.85 in 2024, then decreased by 14.43% to -$0.98 in 2025, then skyrocketed by 364.66% to $2.58 in 2026.
  • Business Quant data shows Debt to Equity for TLSI at $2.58 in Q1 2026, -$0.98 in Q4 2025, and -$1.23 in Q3 2025.